Erdafitinib is intended for the treatment of advanced solid tumours with a mutation in receptors which bind to the fibroblast growth factor family of proteins, called fibroblast growth factor receptors (FGFR), in patients 6 years and older, who have failed at least one previous treatment and children or adolescent patients who are newly diagnosed and have no suitable treatment options. Approximately 5 – 30% of patients who have a solid tumour will have such a mutation, depending on tumour type and site and there are currently no treatments available in the EU/UK which reduce the activity of all four FGFRs so this product represents a new treatment approach in an area of unmet need.
Erdafitinib for treating advanced solid tumours with an FGFR mutation in people aged 6 years and older
Erdafitinib is intended for the treatment of advanced solid tumours with a mutation in receptors which bind to the fibroblast growth factor family of proteins, called fibroblast growth factor receptors (FGFR), in patients 6 years and older, who have failed at least one previous treatment and children or adolescent patients who are newly diagnosed and have no suitable treatment options.